{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T16:56:48Z","timestamp":1793120208071,"version":"4.5.0"},"reference-count":67,"publisher":"MDPI AG","issue":"11","license":[{"start":{"date-parts":[[2022,11,18]],"date-time":"2022-11-18T00:00:00Z","timestamp":1668729600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biomedicines"],"abstract":"<jats:p>Antipsychotic drugs (APs) aim to treat schizophrenia, bipolar mania, and behavioral symptoms. In child psychiatry, despite limited evidence regarding their efficacy and safety, APs are increasingly subject to off-label use. Studies investigating addictology-related symptoms in young people being scarce, we aimed to characterize the different patterns of AP misuse and withdrawal in children and adolescents relying on the WHO pharmacovigilance database (VigiBase\u00ae, Uppsala Monitoring Centre, Sweden). Using the standardized MedDRA Query \u2018drug abuse, dependence and withdrawal\u2019, disproportionality for each AP was assessed with the reporting odds ratio and the information component. A signal was detected when the lower end of the 95% confidence interval of the information component was positive. Results revealed mainly withdrawal symptoms in infants (under 2 years), intentional misuse in children (2 to 11 years), and abuse in adolescents (12 to 17 years). Olanzapine, risperidone, aripiprazole, and quetiapine were disproportionately reported in all age groups, with quetiapine being subject to a specific abuse signal in adolescents. Thus, in adolescents, the evocation of possible recreational consumption may lead to addiction-appropriate care. Further, in young patients with a history of AP treatment, a careful anamnesis may allow one to identify misuse and its role in the case of new-onset symptoms.<\/jats:p>","DOI":"10.3390\/biomedicines10112972","type":"journal-article","created":{"date-parts":[[2022,11,21]],"date-time":"2022-11-21T03:11:21Z","timestamp":1669000281000},"page":"2972","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Antipsychotic Abuse, Dependence, and Withdrawal in the Pediatric Population: A Real-World Disproportionality Analysis"],"prefix":"10.3390","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7669-2339","authenticated-orcid":false,"given":"Diane","family":"Merino","sequence":"first","affiliation":[{"name":"Department of Child and Adolescent Psychiatry, Children\u2019s Hospitals of Nice, CHU-Lenval, 06200 Nice, France"},{"name":"CoBTek Laboratory, Universit\u00e9 C\u00f4te d\u2019Azur, 06000 Nice, France"},{"name":"Pharmacovigilance Center, Department of Pharmacology, University Hospital of Nice, 06000 Nice, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6591-6966","authenticated-orcid":false,"given":"Alexandre O.","family":"G\u00e9rard","sequence":"additional","affiliation":[{"name":"Pharmacovigilance Center, Department of Pharmacology, University Hospital of Nice, 06000 Nice, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandre","family":"Destere","sequence":"additional","affiliation":[{"name":"Pharmacovigilance Center, Department of Pharmacology, University Hospital of Nice, 06000 Nice, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florence","family":"Askenazy","sequence":"additional","affiliation":[{"name":"Department of Child and Adolescent Psychiatry, Children\u2019s Hospitals of Nice, CHU-Lenval, 06200 Nice, France"},{"name":"CoBTek Laboratory, Universit\u00e9 C\u00f4te d\u2019Azur, 06000 Nice, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4703-9765","authenticated-orcid":false,"given":"Milou-Daniel","family":"Drici","sequence":"additional","affiliation":[{"name":"Pharmacovigilance Center, Department of Pharmacology, University Hospital of Nice, 06000 Nice, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9993-6981","authenticated-orcid":false,"given":"Susanne","family":"Th\u00fcmmler","sequence":"additional","affiliation":[{"name":"Department of Child and Adolescent Psychiatry, Children\u2019s Hospitals of Nice, CHU-Lenval, 06200 Nice, France"},{"name":"CoBTek Laboratory, Universit\u00e9 C\u00f4te d\u2019Azur, 06000 Nice, France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,11,18]]},"reference":[{"key":"ref_1","first-page":"19","article-title":"Chlorpromazine and Neuroleptic Treatments in Psychiatry","volume":"17","author":"Delay","year":"1956","journal-title":"J. Clin. Exp. Psychopathol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1002\/syn.890010203","article-title":"Dopamine Receptors and the Dopamine Hypothesis of Schizophrenia","volume":"1","author":"Seeman","year":"1987","journal-title":"Synapse"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0140-6736(08)61764-X","article-title":"Second-Generation versus First-Generation Antipsychotic Drugs for Schizophrenia: A Meta-Analysis","volume":"373","author":"Leucht","year":"2009","journal-title":"Lancet"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"e3784","DOI":"10.1097\/MD.0000000000003784","article-title":"National Trends in Off-Label Use of Atypical Antipsychotics in Children and Adolescents in the United States","volume":"95","author":"Sohn","year":"2016","journal-title":"Medicine"},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Merino, D., Fernandez, A., G\u00e9rard, A.O., Ben Othman, N., Rocher, F., Askenazy, F., Verstuyft, C., Drici, M.-D., and Th\u00fcmmler, S. (2022). Adverse Drug Reactions of Olanzapine, Clozapine and Loxapine in Children and Youth: A Systematic Pharmacogenetic Review. Pharmaceuticals, 15.","DOI":"10.3390\/ph15060749"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1186\/s13034-022-00517-3","article-title":"Emergence of Psychiatric Adverse Events during Antipsychotic Treatment in AP-Na\u00efve Children and Adolescents","volume":"16","author":"Menard","year":"2022","journal-title":"Child Adolesc. Psychiatry Ment. Health"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1097\/01.chi.0000157543.74509.c8","article-title":"Trends in the Use of Typical and Atypical Antipsychotics in Children and Adolescents","volume":"44","author":"Patel","year":"2005","journal-title":"J. Am. Acad. Child Adolesc. Psychiatry"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1001\/archpsyc.63.6.679","article-title":"National Trends in the Outpatient Treatment of Children and Adolescents With Antipsychotic Drugs","volume":"63","author":"Olfson","year":"2006","journal-title":"Arch. Gen. Psychiatry"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"e406","DOI":"10.1097\/MJT.0000000000000894","article-title":"Off-Label Use of Clozapine in Children and Adolescents-A Literature Review","volume":"26","author":"Rachamallu","year":"2019","journal-title":"Am. J. Ther."},{"key":"ref_10","unstructured":"EMA (2022, April 11). EMA: Leponex (Clozapine). Available online: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/referrals\/leponex."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.pnpbp.2013.06.008","article-title":"Can Antipsychotic Treatment Contribute to Drug Addiction in Schizophrenia?","volume":"52","author":"Samaha","year":"2014","journal-title":"Prog. Neuropsychopharmacol. Biol. Psychiatry"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.jsat.2014.07.006","article-title":"Misuse of Atypical Antipsychotics in Conjunction with Alcohol and Other Drugs of Abuse","volume":"48","author":"Malekshahi","year":"2015","journal-title":"J. Subst. Abus. Treat."},{"key":"ref_13","first-page":"1178221819844205","article-title":"Comparison of Quetiapine Abuse and Misuse Reports to the FDA Adverse Event Reporting System With Other Second-Generation Antipsychotics","volume":"13","author":"Evoy","year":"2019","journal-title":"Subst. Abus."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1089\/cyber.2014.0486","article-title":"Mind Navigators of Chemicals\u2019 Experimenters? A Web-Based Description of E-Psychonauts","volume":"18","author":"Orsolini","year":"2015","journal-title":"Cyberpsychol. Behav. Soc. Netw."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"4646","DOI":"10.1111\/bcp.15420","article-title":"Abuse and Misuse of Second-generation Antipsychotics: An Analysis Using VigiBase, the World Health Organisation Pharmacovigilance Database","volume":"88","author":"Roy","year":"2022","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Chiappini, S., and Schifano, F. (2020). What about \u201cPharming\u201d? Issues Regarding the Misuse of Prescription and Over-the-Counter Drugs. Brain Sci., 10.","DOI":"10.3390\/brainsci10100736"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1093\/bmb\/ldw016","article-title":"Digital Danger: A Review of the Global Public Health, Patient Safety and Cybersecurity Threats Posed by Illicit Online Pharmacies","volume":"118","author":"Mackey","year":"2016","journal-title":"Br. Med. Bull."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1159\/000507897","article-title":"Coming Off Prescribed Psychotropic Medications: Insights from Their Use as Recreational Drugs","volume":"89","author":"Schifano","year":"2020","journal-title":"Psychother. Psychosom."},{"key":"ref_19","first-page":"409","article-title":"VigiBase, the WHO Global ICSR Database System: Basic Facts","volume":"42","author":"Lindquist","year":"2008","journal-title":"Ther. Innov. Regul. Sci."},{"key":"ref_20","unstructured":"(2022, September 26). Uppsala Monitoring Centre About VigiBase. Available online: https:\/\/who-umc.org\/vigibase\/."},{"key":"ref_21","unstructured":"Centre, U.M. (2022, April 28). Uppsala Monitoring Centre. Available online: https:\/\/who-umc.org\/."},{"key":"ref_22","first-page":"316","article-title":"Characterization of Serious Adverse Drug Reactions in Hospital to Determine Potential Implications of Mandatory Reporting","volume":"71","author":"Gautron","year":"2018","journal-title":"Can. J. Hosp. Pharm."},{"key":"ref_23","unstructured":"(2022, April 29). CFR\u2014Code of Federal Regulations Title 21, Available online: https:\/\/www.accessdata.fda.gov\/scripts\/cdrh\/cfdocs\/cfcfr\/CFRSearch.cfm?fr=312.32."},{"key":"ref_24","unstructured":"(2021, September 03). MedDRA Hierarchy|MedDRA. Available online: https:\/\/www.meddra.org\/how-to-use\/basics\/hierarchy."},{"key":"ref_25","unstructured":"(2020, August 09). Standardised MedDRA Queries|MedDRA. Available online: https:\/\/www.meddra.org\/standardised-meddra-queries."},{"key":"ref_26","unstructured":"Markides, K. (2007). Adverse Drug Withdrawal Events. Encyclopedia of Health & Aging, SAGE Publications, Inc."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1002\/pds.1742","article-title":"Quantitative Signal Detection Using Spontaneous ADR Reporting: QUANTITATIVE SIGNAL DETECTION","volume":"18","author":"Bate","year":"2009","journal-title":"Pharmacoepidemiol. Drug Saf."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.therap.2019.01.006","article-title":"Case\u2013Non-Case Studies: Principle, Methods, Bias and Interpretation","volume":"74","author":"Faillie","year":"2019","journal-title":"Therapies"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1007\/s002280050466","article-title":"A Bayesian Neural Network Method for Adverse Drug Reaction Signal Generation","volume":"54","author":"Bate","year":"1998","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1517\/14656566.2015.1041501","article-title":"Antipsychotic Use in Pregnancy","volume":"16","author":"Kulkarni","year":"2015","journal-title":"Expert Opin. Pharmacother."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1007\/s40263-018-0517-5","article-title":"The Safety of Second-Generation Antipsychotics During Pregnancy: A Clinically Focused Review","volume":"32","author":"Damkier","year":"2018","journal-title":"CNS Drugs"},{"key":"ref_32","unstructured":"(2022, September 17). FDA-Approved Drugs: Zyprexa, Available online: https:\/\/www.accessdata.fda.gov\/scripts\/cder\/daf\/index.cfm?event=overview.process&ApplNo=020592."},{"key":"ref_33","unstructured":"(2022, September 17). FDA-Approved Drugs: Seroquel, Available online: https:\/\/www.accessdata.fda.gov\/scripts\/cder\/daf\/index.cfm?event=overview.process&ApplNo=020639."},{"key":"ref_34","unstructured":"(2022, September 17). FDA-Approved Drugs: Abilify, Available online: https:\/\/www.accessdata.fda.gov\/scripts\/cder\/daf\/index.cfm?event=overview.process&ApplNo=021436."},{"key":"ref_35","unstructured":"(2022, September 17). FDA-Approved Drugs: Risperdal, Available online: https:\/\/www.accessdata.fda.gov\/scripts\/cder\/daf\/index.cfm?event=overview.process&ApplNo=020272."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"151230","DOI":"10.1016\/j.semperi.2020.151230","article-title":"Psychotropic Drug Use in Perinatal Women with Bipolar Disorder","volume":"44","author":"Clark","year":"2020","journal-title":"Semin. Perinatol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1038\/clpt.2008.1","article-title":"Effects of Pregnancy on CYP3A and P-glycoprotein Activities as Measured by Disposition of Midazolam and Digoxin: A University of Washington Specialized Center of Research Study","volume":"84","author":"Hebert","year":"2008","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1345\/aph.17215","article-title":"Atypical Antipsychotics. Part I: Pharmacology, Pharmacokinetics, and Efficacy","volume":"33","author":"Markowitz","year":"1999","journal-title":"Ann. Pharmacother."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1176\/appi.ajp.158.3.360","article-title":"Does Fast Dissociation from the Dopamine d(2) Receptor Explain the Action of Atypical Antipsychotics?: A New Hypothesis","volume":"158","author":"Kapur","year":"2001","journal-title":"Am. J. Psychiatry"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1159\/000506868","article-title":"Acute and Persistent Withdrawal Syndromes Following Discontinuation of Psychotropic Medications","volume":"89","author":"Cosci","year":"2020","journal-title":"Psychother. Psychosom."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1017\/S1092852900027449","article-title":"On Categorizing Gestational, Birth, and Neonatal Complications Following Late Pregnancy Exposure to Antidepressants: The Prenatal Antidepressant Exposure Syndrome","volume":"15","author":"Gentile","year":"2010","journal-title":"CNS Spectr."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/j.ejpn.2016.11.003","article-title":"Neonatal Venlafaxine Discontinuation Syndrome: A Mini-Review","volume":"21","author":"Holland","year":"2017","journal-title":"Eur. J. Paediatr. Neurol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1542\/peds.2007-2008","article-title":"Epidemiologic Features of Antipsychotic Prescribing to Children and Adolescents in Primary Care in the United Kingdom","volume":"121","author":"Rani","year":"2008","journal-title":"Pediatrics"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1177\/070674371205700109","article-title":"Ten Years of Antipsychotic Prescribing to Children: A Canadian Population-Based Study","volume":"57","author":"Biscontri","year":"2012","journal-title":"Can. J. Psychiatry"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1177\/070674371305800608","article-title":"A Population-Based Study of Antipsychotic Prescription Trends in Children and Adolescents in British Columbia, from 1996 to 2011","volume":"58","author":"Ronsley","year":"2013","journal-title":"Can. J. Psychiatry"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.ambp.2005.11.002","article-title":"Trends in Prescribing of Antipsychotic Medications for US Children","volume":"6","author":"Cooper","year":"2006","journal-title":"Ambul. Pediatr."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1177\/070674371205701202","article-title":"A Review of Pharmacoepidemiologic Studies of Antipsychotic Use in Children and Adolescents","volume":"57","author":"Patten","year":"2012","journal-title":"Can. J. Psychiatry"},{"key":"ref_48","unstructured":"(2022, September 17). EMA Risperdal. Available online: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/referrals\/risperdal."},{"key":"ref_49","unstructured":"(2022, September 17). EMA Abilify. Available online: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/abilify."},{"key":"ref_50","unstructured":"(2022, April 15). EMA Zyprexa. Available online: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/zyprexa."},{"key":"ref_51","unstructured":"(2022, September 17). EMA Seroquel\/XR and Associated Names. Available online: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/referrals\/seroquel-seroquel-xr-associated-names."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1176\/ajp.135.11.1321","article-title":"Withdrawal syndromes associated with antipsychotic drugs","volume":"135","author":"Gardos","year":"1978","journal-title":"Am. J. Psychiatry"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"178","DOI":"10.5152\/npa.2015.10122","article-title":"Withdrawal-Emergent Dyskinesia and Supersensitivity Psychosis Due to Olanzapine Use","volume":"53","year":"2016","journal-title":"Noro Psikiyatr Ars."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/0920-9964(91)90050-2","article-title":"Severe Cases of Neuroleptic-Induced Supersensitivity Psychosis: Diagnostic Criteria for the Disorder and Its Treatment","volume":"5","author":"Chouinard","year":"1991","journal-title":"Schizophr. Res."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1159\/000112883","article-title":"Atypical Antipsychotics: CATIE Study, Drug-Induced Movement Disorder and Resulting Iatrogenic Psychiatric-Like Symptoms, Supersensitivity Rebound Psychosis and Withdrawal Discontinuation Syndromes","volume":"77","author":"Chouinard","year":"2008","journal-title":"Psychother. Psychosom."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1111\/j.1943-278X.2000.tb01098.x","article-title":"Use of Paracetamol (Acetaminophen) for Suicide and Nonfatal Poisoning: Worldwide Patterns of Use and Misuse","volume":"30","author":"Gunnell","year":"2000","journal-title":"Suicide Life-Threat. Behav."},{"key":"ref_57","unstructured":"(2022, October 01). R\u00e9sum\u00e9 Des Caract\u00e9ristiques Du Produit\u2014TERCIAN 40 Mg\/Ml, Solution Buvable En Gouttes\u2014Base de Donn\u00e9es Publique Des M\u00e9dicaments. Available online: https:\/\/base-donnees-publique.medicaments.gouv.fr\/affichageDoc.php?specid=66615713&typedoc=R#RcpPosoAdmin."},{"key":"ref_58","unstructured":"(2022, September 17). FDA-Approved Drugs: Sparine, Available online: https:\/\/www.accessdata.fda.gov\/scripts\/cder\/daf\/index.cfm?event=overview.process&ApplNo=010942."},{"key":"ref_59","unstructured":"(2022, September 17). FDA-Approved Drugs: Truxal, Available online: https:\/\/www.accessdata.fda.gov\/scripts\/cder\/daf\/index.cfm?event=overview.process&ApplNo=012486."},{"key":"ref_60","unstructured":"(2022, September 17). What Are NPS?. Available online: https:\/\/www.unodc.org\/LSS\/Page\/NPS."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.drugpo.2017.11.003","article-title":"The Diverse Reasons for Using Novel Psychoactive Substances\u2014A Qualitative Study of the Users\u2019 Own Perspectives","volume":"52","author":"Soussan","year":"2018","journal-title":"Int. J. Drug Policy"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/j.therap.2018.12.007","article-title":"Monitoring of Drug Misuse or Potential Misuse in a Nationwide Healthcare Insurance Database: A Cross-Sectional Study in France","volume":"74","author":"Noize","year":"2019","journal-title":"Therapies"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1007\/s00213-008-1226-4","article-title":"Modulation of Striatal Dopamine Release by 5-HT2A and 5-HT2C Receptor Antagonists: [11C]Raclopride PET Studies in the Rat","volume":"200","author":"Egerton","year":"2008","journal-title":"Psychopharmacology"},{"key":"ref_64","first-page":"13","article-title":"Is Seroquel Developing an Illicit Reputation for Misuse\/Abuse?","volume":"7","author":"Sansone","year":"2010","journal-title":"Psychiatry"},{"key":"ref_65","first-page":"SART-S22233","article-title":"Emergency Department Visits Involving Misuse and Abuse of the Antipsychotic Quetiapine: Results from the Drug Abuse Warning Network (DAWN)","volume":"9","author":"Mattson","year":"2015","journal-title":"Subst. Abus."},{"key":"ref_66","first-page":"243","article-title":"Intentional Recreational Abuse of Quetiapine Compared to Other Second-Generation Antipsychotics","volume":"18","author":"Klein","year":"2017","journal-title":"West. J. Emerg. Med. Integr. Emerg. Care Popul. Health"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"385","DOI":"10.2165\/00002018-200629050-00003","article-title":"Under-Reporting of Adverse Drug Reactions: A Systematic Review","volume":"29","author":"Hazell","year":"2006","journal-title":"Drug Saf"}],"container-title":["Biomedicines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2227-9059\/10\/11\/2972\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T01:21:23Z","timestamp":1760145683000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2227-9059\/10\/11\/2972"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,18]]},"references-count":67,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2022,11]]}},"alternative-id":["biomedicines10112972"],"URL":"https:\/\/doi.org\/10.3390\/biomedicines10112972","relation":{},"ISSN":["2227-9059"],"issn-type":[{"value":"2227-9059","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,18]]}}}